Ocular Therapeutix (OCUL) grants CCO RSUs and 197,650 stock options

Rhea-AI Filing Summary

Ocular Therapeutix Chief Commercial Officer Steve Lawrence Meyers reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and additional one-third portions vesting at the end of each of the next two years, subject to continued service.

He was also granted a stock option covering 197,650 shares of common stock at an exercise price of $11.82 per share. This option vests over four years in equal monthly installments of 1/48 of the shares beginning one month after the grant date, contingent on continued service. Following these transactions, he beneficially owned 217,628 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meyers Steve Lawrence

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		64,900(1)	A	$0	217,628	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.82	01/02/2026		A		197,650		(2)	01/01/2036	Common Stock	197,650	$0	197,650	D

Explanation of Responses:

1. On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

2. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

	/s/ Todd Anderman, Attorney-in-Fact for Steve Lawrence Meyers	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Ocular Therapeutix (OCUL) report for Steve Meyers?

The filing reports that Chief Commercial Officer Steve Lawrence Meyers received 64,900 restricted stock units and a stock option for 197,650 shares of Ocular Therapeutix common stock on January 2, 2026.

How many Ocular Therapeutix RSUs were granted to the CCO and how do they vest?

Steve Meyers was granted 64,900 RSUs. Subject to his continued service, one-third vests on the first anniversary of the January 2, 2026 grant date, and an additional one-third vests at the end of each of the next two years.

What are the terms of the Ocular Therapeutix stock options granted to the CCO?

The filing shows a grant of a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share. The option vests over four years, with 1/48 of the shares vesting monthly beginning one month after the grant date, subject to continued service.

Did the Ocular Therapeutix CCO pay cash for the RSU and option grants?

No cash was paid for the equity awards at grant. The RSUs were granted at $0, and the stock option was granted at $0 cost but is exercisable at an $11.82 per-share exercise price.

How many Ocular Therapeutix shares does the CCO own after these transactions?

After the reported transactions, Chief Commercial Officer Steve Meyers beneficially owned 217,628 shares of Ocular Therapeutix common stock directly.

Under which plan were the Ocular Therapeutix RSUs granted to the CCO?

The 64,900 RSUs were granted under Ocular Therapeutix’s 2021 Stock Incentive Plan, as amended, with each RSU representing the right to receive one share of common stock upon vesting.